People with myelodysplastic syndrome (MDS) who received azacytidine and achieved complete cytogenetic response (CCyR) experienced better overall survival than those who did not achieve such, according to a study involving >700 individuals. Participants had either higher risk MDS or low blast count acute myeloid leukemia, and included those with abnormal karyotype. Investigators looked at the prognostic impact of baseline cytogenetics and cytogenic response (CyR) on overall response and survival rates. In 281 evaluable patients with abnormal cytogenics:
- CyR was achieved in ~one-third.
- CCyR was attained in one-fourth.
- CyR did not impact survival overall.
- Those with MDS who achieved CCyR experienced better overall survival.
Sébert M, Komrokji R, Sekeres M, et al. Impact of baseline cytogenetic findings and cytogenetic response on outcome of high-risk myelodysplastic syndromes and low blast count AML treated with azacitidine. Leuk Res. 2017;63:72-77. doi:10.1016/j.leukres.2017.10.013.
This Week's Must Reads
Must Reads in AML
Azacitidine in Lower-Risk MDS Shows Promise, Oncologist; ePub 2017 Nov 8; Komrokji, et al
Clostridium Difficile Infection in People with MDS, World J Clin Oncol; 2017 Oct 10; Shaht, et al
Survival in Azacitidine-Treated Patients Assessed, Leuk Res; 2017 Oct 27; Sébert, Komrokji et al
Use This to Evaluate MRD Prior to Allo-SCT, Leuk Res; 2017 Dec; Candoni, De Marchi, et al
Detecting Minimal Residual Disease in AML, Curr Hematol Malig Rep; ePub 2017 Nov 2; Zhou, et al